eCite Digital Repository

Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-na´ve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Citation

Currie, CJ and McEwan, P and Poole, C and Valentine, WJ and Palmer, AJ and Lammert, M and Nicklasson, L and Foos, V and Roze, S, Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting, Current Medical Research and Opinion, 22, (5) pp. 967-969. ISSN 0300-7995 (2006) [Letter or Note in Journal]

DOI: doi:10.1185/030079906X00000

Item Details

Item Type:Letter or Note in Journal
Research Division:Economics
Research Group:Applied Economics
Research Field:Health Economics
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:74665
Year Published:2006
Web of Science® Times Cited:2
Deposited By:Research Division
Deposited On:2011-12-09
Last Modified:2011-12-13
Downloads:0

Repository Staff Only: item control page